Metabolic Plasticity in Melanoma Progression and Response to Oncogene Targeted Therapies
- Author(s)
- Alkaraki, A; McArthur, GA; Sheppard, KE; Smith, LK;
- Details
- Publication Year 2021-11,Volume 13,Issue #22,Page 5810
- Journal Title
- Cancers
- Publication Type
- Review
- Abstract
- Resistance to therapy continues to be a barrier to curative treatments in melanoma. Recent insights from the clinic and experimental settings have highlighted a range of non-genetic adaptive mechanisms that contribute to therapy resistance and disease relapse, including transcriptional, post-transcriptional and metabolic reprogramming. A growing body of evidence highlights the inherent plasticity of melanoma metabolism, evidenced by reversible metabolome alterations and flexibility in fuel usage that occur during metastasis and response to anti-cancer therapies. Here, we discuss how the inherent metabolic plasticity of melanoma cells facilitates both disease progression and acquisition of anti-cancer therapy resistance. In particular, we discuss in detail the different metabolic changes that occur during the three major phases of the targeted therapy response-the early response, drug tolerance and acquired resistance. We also discuss how non-genetic programs, including transcription and translation, control this process. The prevalence and diverse array of these non-genetic resistance mechanisms poses a new challenge to the field that requires innovative strategies to monitor and counteract these adaptive processes in the quest to prevent therapy resistance.
- Department(s)
- Laboratory Research; Medical Oncology
- PubMed ID
- 34830962
- Publisher's Version
- https://doi.org/10.3390/cancers13225810
- Open Access at Publisher's Site
https://doi.org/10.3390/cancers13225810- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2025-05-23 04:02:52
Last Modified: 2025-05-23 04:04:10